Cargando…

The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma

Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving (131)I therapy. Seventy patients were stratified into two groups: the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haiying, Jiao, Ling, Cui, Songye, Wang, Liang, Tan, Jian, Zhang, Guizhi, He, Yajing, Ruan, Shuzhou, Fan, Saijun, Zhang, Wenyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211018/
https://www.ncbi.nlm.nih.gov/pubmed/25337944
http://dx.doi.org/10.3390/ijerph111010991
_version_ 1782341495692460032
author Zhang, Haiying
Jiao, Ling
Cui, Songye
Wang, Liang
Tan, Jian
Zhang, Guizhi
He, Yajing
Ruan, Shuzhou
Fan, Saijun
Zhang, Wenyi
author_facet Zhang, Haiying
Jiao, Ling
Cui, Songye
Wang, Liang
Tan, Jian
Zhang, Guizhi
He, Yajing
Ruan, Shuzhou
Fan, Saijun
Zhang, Wenyi
author_sort Zhang, Haiying
collection PubMed
description Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving (131)I therapy. Seventy patients were stratified into two groups: the ablation group (A) and the follow-up group (FU). The patients’ external dose rate was measured, and simultaneously, their retained body radiation activity was monitored at various time points. The equations of the external dose rate and the retained body activity, described as a function of hours post administration, were fitted. Additionally, the release time for patients was calculated. The reduction in activity in the group receiving a second or subsequent treatment was more rapid than the group receiving only the initial treatment. Most important, an expeditious method was established to indirectly evaluate the retained body activity of patients by measuring the external dose rate with a portable radiation survey meter. By this method, the calculated external dose rate limits are 19.2, 8.85, 5.08 and 2.32 μSv·h(−1) at 1, 1.5, 2 and 3 m, respectively, according to a patient’s released threshold level of retained body activity <400 MBq. This study is beneficial for radiation safety decision-making.
format Online
Article
Text
id pubmed-4211018
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42110182014-10-28 The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma Zhang, Haiying Jiao, Ling Cui, Songye Wang, Liang Tan, Jian Zhang, Guizhi He, Yajing Ruan, Shuzhou Fan, Saijun Zhang, Wenyi Int J Environ Res Public Health Article Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving (131)I therapy. Seventy patients were stratified into two groups: the ablation group (A) and the follow-up group (FU). The patients’ external dose rate was measured, and simultaneously, their retained body radiation activity was monitored at various time points. The equations of the external dose rate and the retained body activity, described as a function of hours post administration, were fitted. Additionally, the release time for patients was calculated. The reduction in activity in the group receiving a second or subsequent treatment was more rapid than the group receiving only the initial treatment. Most important, an expeditious method was established to indirectly evaluate the retained body activity of patients by measuring the external dose rate with a portable radiation survey meter. By this method, the calculated external dose rate limits are 19.2, 8.85, 5.08 and 2.32 μSv·h(−1) at 1, 1.5, 2 and 3 m, respectively, according to a patient’s released threshold level of retained body activity <400 MBq. This study is beneficial for radiation safety decision-making. MDPI 2014-10-21 2014-10 /pmc/articles/PMC4211018/ /pubmed/25337944 http://dx.doi.org/10.3390/ijerph111010991 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Haiying
Jiao, Ling
Cui, Songye
Wang, Liang
Tan, Jian
Zhang, Guizhi
He, Yajing
Ruan, Shuzhou
Fan, Saijun
Zhang, Wenyi
The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
title The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
title_full The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
title_fullStr The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
title_full_unstemmed The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
title_short The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
title_sort study of external dose rate and retained body activity of patients receiving (131)i therapy for differentiated thyroid carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211018/
https://www.ncbi.nlm.nih.gov/pubmed/25337944
http://dx.doi.org/10.3390/ijerph111010991
work_keys_str_mv AT zhanghaiying thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT jiaoling thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT cuisongye thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT wangliang thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT tanjian thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT zhangguizhi thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT heyajing thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT ruanshuzhou thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT fansaijun thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT zhangwenyi thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT zhanghaiying studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT jiaoling studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT cuisongye studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT wangliang studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT tanjian studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT zhangguizhi studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT heyajing studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT ruanshuzhou studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT fansaijun studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma
AT zhangwenyi studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma